drugset / Trial / NCT05549557
IMM40H Phase I Dose Escalation and Expansion
NaSingle-groupOpen-labelTreatment
Summary
This is first-in-human, open-label, multi-center, dose-escalation (phase Ia) and cohort expansion (phase Ib) phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, immunogenicity, and antitumor activities of IMM40H in patients with advanced malignancies including solid tumor and hematological malignancies.
Timeline
- Start
- 2022-09
- Primary completion
- 2023-10
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM40H | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | IMM40H | Monoclonal antibody | 1 mg/kg | — |
| Subject | IMM40H | Monoclonal antibody | 3 mg/kg | — |
| Subject | IMM40H | Monoclonal antibody | 10 mg/kg | — |
| Subject | IMM40H | Monoclonal antibody | 20 mg/kg | — |